PD-1/PD-L1 interaction inhibitors described in Shanghai Maxinovel Pharmaceuticals patent
July 19, 2023
Shanghai Maxinovel Pharmaceuticals Co. Ltd. has reported the identification of programmed cell death 1 (PD-1; PDCD1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer.
